A well-tolerated innate immunotherapy to treat cancer by trageting and reprogramming bone marrow progenitor cells
Poster-1178-RIDE-001_FINAL_v2
A well-tolerated innate immunotherapy to treat cancer by trageting and reprogramming bone marrow progenitor cells
Poster-1178-RIDE-001_FINAL_v2
Trained Therapeutix Discovery Demonstrates RIDE-001 Trains Myeloid Cells for Anti-Tumor Immune Response in Preclinical Data Presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
Trained Therapeutix Discovery Demonstrates RIDE-001 Trains Myeloid Cells for Anti-Tumor Immune Response in Preclinical Data Presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting -RIDE-001, a first-in-class nanomedicine, effectively trained myeloid progenitor cells to elicit myeloid-driven anticancer innate immune responses, as demonstrated in preclinical studies across multiple species Dallas, TTxD & The Netherlands…
Trained Therapeutix Discovery Appoints Joost Kreijtz, PhD, as Chief Executive Officer of Dutch Subsidiary Trained Therapeutix Discovery (NL)
Trained Therapeutix Discovery Appoints Joost Kreijtz, PhD, as Chief Executive Officer of Dutch Subsidiary Trained Therapeutix Discovery (NL) Dallas, TX & The Netherlands — October 17, 2025 — Trained Therapeutix Discovery, Inc., a biotech company training immunity at its origin with nanomedicines, today announced that Joost Kreijtz, PhD, has been appointed Chief Executive Officer of Trained Therapeutix…
Trained Therapeutix Discovery to attend BIO-Europe in Vienna, November 3–5, 2025
Trained Therapeutix Discovery is pleased to announce its participation in BIO-Europe, taking place in Vienna from November 3 to 5, 2025. Our management team will be present and welcomes meeting requests to discuss our cutting-edge nanomedicine programs including our lead programs RIDE-001 and RIDE-002. We are open to opportunities for strategic partnerships and investments. BIO-Europe…